• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Recurrent Pneumonitis Induced by Atezolizumab (Anti-Programmed Death Ligand 1) in NSCLC Patients Who Previously Experienced Anti-Programmed Death 1 Immunotherapy-Related Pneumonitis.

作者信息

Hsu Ping-Chih, Li Shih-Hong, Yang Cheng-Ta

机构信息

Department of Thoracic Medicine, Chung Gung Memorial Hospital, Linkou, Taiwan.

College of Medicine, Chung Gung University and the Department of Thoracic Medicine, Chung Gung Memorial Hospital, Taoyuan, Taiwan.

出版信息

J Thorac Oncol. 2018 Nov;13(11):e227-e230. doi: 10.1016/j.jtho.2018.06.022.

DOI:10.1016/j.jtho.2018.06.022
PMID:30368415
Abstract
摘要

相似文献

1
Recurrent Pneumonitis Induced by Atezolizumab (Anti-Programmed Death Ligand 1) in NSCLC Patients Who Previously Experienced Anti-Programmed Death 1 Immunotherapy-Related Pneumonitis.在先前经历过抗程序性死亡蛋白1免疫治疗相关肺炎的非小细胞肺癌患者中，阿替利珠单抗（抗程序性死亡配体1）诱发的复发性肺炎
J Thorac Oncol. 2018 Nov;13(11):e227-e230. doi: 10.1016/j.jtho.2018.06.022.
2
Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials.非小细胞肺癌中使用程序性死亡1和程序性死亡配体1抑制剂后肺炎的发生率：试验的系统评价和荟萃分析
Chest. 2017 Aug;152(2):271-281. doi: 10.1016/j.chest.2017.04.177. Epub 2017 May 10.
3
Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report.一例难治性转移性肺鳞状细胞癌患者在持久临床缓解前出现严重的纳武单抗诱导性肺炎：病例报告
J Hematol Oncol. 2017 Feb 28;10(1):64. doi: 10.1186/s13045-017-0433-z.
4
Development of Halo Nevi in a Lung Cancer Patient: A Novel Immune-Related Cutaneous Event from Atezolizumab.一名肺癌患者出现晕痣：阿替利珠单抗引发的一种新型免疫相关皮肤事件。
J Drugs Dermatol. 2017 Oct 1;16(10):1047-1049.
5
Fatal outcome of atezolizumab in a patient with immune-mediated pneumonitis, thrombocytopenia, and cardiac dysfunction: A case report
.阿特珠单抗治疗一名伴有免疫介导性肺炎、血小板减少症和心脏功能障碍患者的致命结局：一例病例报告
Int J Clin Pharmacol Ther. 2019 Dec;57(12):607-611. doi: 10.5414/CP203448.
6
Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer.抗 PD-1 抑制剂相关的非小细胞肺癌性肺炎。
Cancer Immunol Res. 2016 Apr;4(4):289-93. doi: 10.1158/2326-6066.CIR-15-0267. Epub 2016 Feb 10.
7
Nintedanib allows retreatment with atezolizumab of combined non-small cell lung cancer/idiopathic pulmonary fibrosis after atezolizumab-induced pneumonitis: a case report.尼达尼布允许在因阿特珠单抗引起的肺炎后，对联合非小细胞肺癌/特发性肺纤维化用阿特珠单抗进行重新治疗：一例报告。
BMC Pulm Med. 2019 Aug 22;19(1):156. doi: 10.1186/s12890-019-0920-9.
8
Immune mediated colitis caused by lung cancer treatment with atezolizumab.阿替利珠单抗治疗肺癌引起的免疫介导性结肠炎。
Rev Esp Enferm Dig. 2017 Dec;109(12):863-864. doi: 10.17235/reed.2017.5060/2017.
9
Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer.纳武利尤单抗相关的间质性肺病分析：两项复发或晚期非小细胞肺癌患者的 II 期研究。
Lung Cancer. 2017 Feb;104:111-118. doi: 10.1016/j.lungcan.2016.12.016. Epub 2016 Dec 21.
10
Immunosuppression for Immune Checkpoint-related Toxicity Can Cause Pneumocystis Jirovecii Pneumonia (PJP) in Non-small-cell Lung Cancer (NSCLC): A Report of 2 Cases.免疫检查点相关毒性的免疫抑制可导致非小细胞肺癌（NSCLC）患者发生耶氏肺孢子菌肺炎（PJP）：2例报告
Clin Lung Cancer. 2019 May;20(3):e247-e250. doi: 10.1016/j.cllc.2018.12.006. Epub 2018 Dec 19.

引用本文的文献

1
SARS-CoV-2 infection heightens the risk of developing HPV-related carcinoma in situ and cancer.新型冠状病毒2型（SARS-CoV-2）感染会增加患人乳头瘤病毒（HPV）相关原位癌和癌症的风险。
Discov Oncol. 2025 Aug 14;16(1):1552. doi: 10.1007/s12672-025-03403-4.
2
A Clinical Analysis of Anti-Programmed Death-Ligand 1 (PD-L1) Immune Checkpoint Inhibitor Treatments Combined with Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer.抗程序性死亡配体1（PD-L1）免疫检查点抑制剂联合化疗治疗初治广泛期小细胞肺癌的临床分析
Vaccines (Basel). 2024 Apr 29;12(5):474. doi: 10.3390/vaccines12050474.
3
TFAP2A promotes cervical cancer via a positive feedback pathway with PD‑L1.
TFAP2A 通过与 PD-L1 的正反馈通路促进宫颈癌。
Oncol Rep. 2023 Jun;49(6). doi: 10.3892/or.2023.8551. Epub 2023 Apr 21.
4
Safety of Tepotinib Challenge after Capmatinib-Induced Pneumonitis in a Patient with Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation: A Case Report.特泊替尼挑战治疗在非小细胞肺癌伴 MET 外显子 14 跳跃突变患者中因卡马替尼引起的肺炎后的安全性：一例报告。
Int J Mol Sci. 2022 Oct 5;23(19):11809. doi: 10.3390/ijms231911809.
5
Case report: Pneumonia with clinical symptoms precedes imaging evidence after immune checkpoint inhibitors combined with radiotherapy in lung squamous cell cancer.病例报告：在免疫检查点抑制剂联合放疗治疗肺鳞癌中，肺炎的临床症状先于影像学证据出现。
Front Immunol. 2022 Sep 15;13:998516. doi: 10.3389/fimmu.2022.998516. eCollection 2022.
6
First line Immunotherapy for Non-Small Cell Lung Cancer.非小细胞肺癌的一线免疫疗法。
Pharmaceuticals (Basel). 2020 Nov 8;13(11):373. doi: 10.3390/ph13110373.
7
High-Risk HPV Oncoproteins and PD-1/PD-L1 Interplay in Human Cervical Cancer: Recent Evidence and Future Directions.高危型人乳头瘤病毒癌蛋白与PD-1/PD-L1在子宫颈癌中的相互作用：最新证据与未来方向
Front Oncol. 2020 Jun 30;10:914. doi: 10.3389/fonc.2020.00914. eCollection 2020.
8
PD-1/PD-L1 Inhibitors in Cervical Cancer.宫颈癌中的PD-1/PD-L1抑制剂
Front Pharmacol. 2019 Feb 1;10:65. doi: 10.3389/fphar.2019.00065. eCollection 2019.